Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Accumulated Expenses (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Accumulated Expenses for 14 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 106.22% year-over-year to $20.0 million, compared with a TTM value of $20.0 million through Dec 2025, up 106.22%, and an annual FY2025 reading of $20.0 million, up 106.22% over the prior year.
  • Accumulated Expenses was $20.0 million for Q4 2025 at Fate Therapeutics, up from $17.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $42.4 million in Q4 2021 and bottomed at $5.4 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $18.3 million, with a median of $17.3 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses surged 488.79% in 2021, then plummeted 82.82% in 2024.
  • Year by year, Accumulated Expenses stood at $42.4 million in 2021, then plummeted by 57.8% to $17.9 million in 2022, then tumbled by 40.99% to $10.6 million in 2023, then dropped by 8.08% to $9.7 million in 2024, then surged by 106.22% to $20.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for FATE at $20.0 million in Q4 2025, $17.6 million in Q3 2025, and $7.1 million in Q2 2025.